Coherus Confident On Avastin This Year With Humira Goal Achieved
Filing Of Adalimumab Was Slated For Q4 2020
Having delivered on a goal to file its Humira biosimilar with the FDA by the end of last year, Coherus BioSciences is now focused on getting its in-licensed bevacizumab product filing over the line, as it scans the market for further growth opportunities.
You may also be interested in...
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.